Abstract

Parthenolide (PTL), a major active sesquiterpene lactone from the herbal plant Tanacetum parthenium, has been applied in traditional Chinese medicine for centuries. Although PTL demonstrates potent anticancer efficacy in numerous types of malignant cells, the cellular targets of PTL have not been well defined. We reported here that PTL interacts with both cytosolic thioredoxin reductase (TrxR1) and mitochondrial thioredoxin reductase (TrxR2), two ubiquitous selenocysteine-containing antioxidant enzymes, to elicit reactive oxygen species-mediated apoptosis in HeLa cells. PTL selectively targets the selenocysteine residue in TrxR1 to inhibit the enzyme function, and further shifts the enzyme to an NADPH oxidase to generate superoxide anions, leading to reactive oxygen species accumulation and oxidized thioredoxin. Under the conditions of inhibition of TrxRs in cells, PTL does not cause significant alteration of cellular thiol homeostasis, supporting selective target of TrxRs by PTL. Importantly, overexpression of functional TrxR1 or Trx1 confers protection, whereas knockdown of the enzymes sensitizes cells to PTL treatment. Targeting TrxRs by PTL thus discloses an unprecedented mechanism underlying the biological activity of PTL, and provides deep insights to understand the action of PTL in treatment of cancer.

Highlights

  • The highly conserved and ubiquitous thioredoxin system, composed of thioredoxin reductase (TrxR),2 thioredoxin (Trx), and NADPH, plays pivotal roles in maintaining intracellular redox homeostasis and regulating multiple redox signaling pathways [1,2,3]

  • Selective inhibition of wild type (WT) TrxR1 but not U498C TrxR1 or glutathione reductase (GR) suggests the Sec residue is targeted by PTL

  • As generation of reactive oxygen species (ROS) is a byproduct of cell growth and metabolism, tumor cells usually have increased ROS levels compared with normal cells [61, 62]

Read more

Summary

Parthenolide Inhibits Thioredoxin Reductase

As our continuous efforts in discovering and developing novel small molecules manipulating the cellular redox system as potential therapeutic agents, we reported here that both TrxR1 and TrxR2 are novel cellular targets of PTL in human cervical carcinoma HeLa cells. PTL appears binding to the Sec residue of TrxRs to suppress their Trx-reduction ability, but further elicits a new function to generate ROS, leading to disruption of cellular redox homeostasis, and eventual induction of apoptosis. Overexpression of the functional TrxR1 or Trx attenuates the cytotoxicity of PTL, whereas knockdown of TrxR1 or TrxR2 enhances the cytotoxicity, supporting the physiological significance of interaction of TrxRs with PTL. Targeting TrxRs by PTL reveals an unprecedented mechanism underlying the biological action of PTL, and would shed light on the potential application of PTL in the treatment of cancer

Experimental Procedures
Results
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call